Human Vaccines & Immunotherapeutics

ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage:

Letter from the Editor Ronald W. Ellis & Eva M. Riedmann To cite this article: Ronald W. Ellis & Eva M. Riedmann (2015) Letter from the Editor, Human Vaccines & Immunotherapeutics, 11:1, 1-2, DOI: 10.4161/hv.36805 To link to this article:

Copyright © 2015 Landes Bioscience

Published online: 01 Nov 2014.

Submit your article to this journal

Article views: 111

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at Download by: [New York University]

Date: 17 November 2015, At: 17:23

Editor's Editor'sCorner

Editor's Corner

Human Vaccines & Immunotherapeutics 11:1, 1–2; January 2015; © 2015 Landes Bioscience

Letter from the Editor Ronald Ellis1,* and Eva M Riedmann2 Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria


Dear Reader, We want to take this opportunity to wish you all a happy, healthy and prosperous new year!

Downloaded by [New York University] at 17:23 17 November 2015

Human Vaccines & Immunotherapeutics (HV&I) has completed10 years of publication! During this time, our journal has become well-established in the scientific community as an important platform for publishing vaccine- and immunotherapy-related research. The number of submissions as well as their quality have been steadily increasing. Moreover, we are pleased to collaborate with various conference organizers to produce Meeting Supplements based on vaccine and/or immunotherapy conferences. In 2011 and 2013 we published Meeting Supplements based on the 7th and 8th World Congress on Vaccines, Immunization and Immunotherapy (WCVII), respectively. We are pleased to do so again in this issue for the recent 9th WCVII. Dr Edouard Kurstak, President of the WCVII and of the Infectious Control World Organization (ICWO), has kindly served as Guest-Editor for this Supplement. The current issue features 43 selected papers prepared by speakers of the WCVII 2014. The manuscripts fall into five categories: (I) Towards new vaccines, immunization strategy and immunotherapy; (II) Advances in prevention, epidemiological analysis and immunization; (III) Vaccination among the elderly population: safety and tolerability; (IV) The impact of long term vaccination on infection epidemiology; (V) Effectiveness and economic benefits of vaccination. In his editorial introduction, Dr Kurstak provides an overview of the conference, which is devoted to the development of new immunogenic and safe vaccines. This meeting was an excellent platform for presenting the latest research on immunization and immunotherapy, and a good opportunity for networking and lively discussion (Kurstak, p 3). The first part of our Special Issue—Towards new vaccines, immunization strategy and immunotherapy—features four review articles on vaccine development against Neisseria meningitidis serogroup B disease (Zlotnick, p 5), vaccination against respiratory Pseudomonas aeruginosa infection (Grimwood, p 14), measles virus as a pathogen, vaccine and vector (Naim, p 21), and tailored immunity by skin antigen-presenting cells (Levin, p 27). Also in this section, we present studies on the use of mimotope-based immunotherapy in a breast cancer patient (Makhoul, p 37), anti-tumor effects of DNA vaccines against HPV major oncogenes (Cordeiro, p 45), hepatitis B vaccination and the problem of escape mutant viruses (Romanò, p 53), immune responses to hepatitis B vaccine in patients with diabetes and celiac disease (Zanoni, p 58), impact of universal vaccination against varicella in Italy (Bechini, p 63), and new media to improve vaccine uptake and coverage (Odone, p 72). The second part of our Special Issue—Advances in prevention, epidemiological analysis and immunization—features studies on an immune-competent mouse model for the characterization of recombinant measles vaccines (Marty, p 83), routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety (Alicino, p 91), influenza vaccination among Italian healthcare workers (Alicino, p 95), reducing the burden of herpes zoster in Italy (Gabutti, p 101), and the epidemiology and prevention of pertussis (Gabutti, p 108). Two studies on plant-based vaccines look at the immunogenicity of H1N1 influenza virus-like particles produced in tobacco plants (Shoji, p 118) and a novel plant-produced Pfs25 fusion subunit vaccine that induces long-lasting transmission blocking antibody responses (Jones, p 124). Moreover, there are studies on low vaccination coverage among Italian healthcare workers (Fortunato, p 133), factors associated with poor adherence to MMR vaccination in parents whose children would follow the vaccination schedule (Restivo, p 140), and the opinion of family pediatricians on compulsory vaccinations for children (Martinelli, p 146). The third section—Vaccination among the elderly population: safety and tolerability—presents papers on current recommendations and future prospects of adult vaccination (Swanson, p 150), retrospective analysis of hospital discharge records for Streptococcus pneumonia diseases in the elderly and implications for immunization policies (Bechini, p 156), and the potential effect *Correspondence to: Ronald Ellis; Email: [email protected] Submitted: 10/10/2014; Accepted: 10/10/2014

Human Vaccines & Immunotherapeutics 1

of PCV13 introduction on Emergency Department access for lower respiratory tract infections in elderly and at-risk adults (Ansaldi, p 166). There are also studies on the safety and tolerability of pneumococcal conjugate vaccine in the elderly (Durando, p 172), epidemiology and costs of herpes zoster and postherpetic neuralgia in persons aged 50 years and older (Salleras, p 178), as well as the burden of herpes zoster disease in Tuscany (Levi, p 185).

Downloaded by [New York University] at 17:23 17 November 2015

The fourth part—The impact of long term vaccination on infection epidemiology—contains studies on changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program (Martínez, p 192), ten years of influenza surveillance in Northern Italy (Pariani, p 198), and surveillance and vaccination coverage of measles and rubella in Northern Italy (Amendola, p 206). Also in this section are studies on the effectiveness of varicella vaccination in children under five years of age (Tafuri, p 214), efforts to achieve elimination of congenital rubella syndrome and rubella (Cozza, p 220), and the assessment of influenza vaccine effectiveness through sentinel virological data in three post-pandemic seasons (Torner, p 225). Finally, this section features papers on the characteristics of pertussis outbreaks in Catalonia, Spain (Crespo, p 231), impact of ten years of infant universal varicella vaccination in Sicily, Italy (Amodio, p 236), as well as facilitators and barriers for HPV unvaccinated girls (Firenze, p 240). The last part in this Special Issue—Effectiveness and economic benefits of vaccination—features studies on the evaluation of the economic burden of herpes zoster infection (Panatto, p 245), seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients (Sticchi, p 263), Chlamydia trachomatis prevalence and chlamydial/HPV co-infection among HPV-unvaccinated young females (Panatto, p 270), and surveillance of acute flaccid paralysis (AFP) in Lombardy, Northern Italy, in the context of the national AFP surveillance system (Pellegrinelli, p 277). Moreover, this track has studies on viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain (Barrabeig, p 282), the role of healthcare personnel in measles transmission and the need for updated immunization status (Torner, p 288), a seroprevalence study of Bordetella pertussis infection in healthcare workers (Urbiztondo, p 293), as well as the use of generalized linear additive and mixed models to estimate influenza cases (Oviedo, p 298). As usual, the WCVII 2014 has covered a lot of important ground, which is well reflected in the great variety of contributions in this Meeting Supplement. This Special Issue is a valuable summary and source of information for attendees of this congress, and even more so for those scientists and medical specialists who missed the meeting. Sincerely, Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor


Human Vaccines & Immunotherapeutics

Volume 11 Issue 1

Letter from the editor.

Letter from the editor. - PDF Download Free
765KB Sizes 0 Downloads 4 Views